is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Surgical site infections (SSIs) are now the most frequently reported health care–associated infection (HAI) in the United States. In Australia, infection of the surgical site occurs in approximately 3% of surgical procedures.
Reported rates of surgical site infections vary according to the surgical procedure; 1–2% for clean surgical procedures (Class 1) and >20% for selective colorectal procedures (Class 3).
In a selective example, a single centre in Melbourne documented an infection rate associated with hip and knee arthroplasty at approximately 5%.4 These SSIs were associated with a significant increased cost for arthroplasty (61% increased cost, p<0.001), including increased length of stay.The authors indicated that these high costs were unsustainable and that development of effective, evidence-based interventional strategies was strongly warranted.
In 2006, in an effort to improve surgical outcomes in the United States, the Center for Medicare and Medicaid Services (CMS) introduced the Surgical Care Improvement Project (SCIP). SCIP focused on four ‘core’ measures:
Each of these measures had peer evidence-based publications to validate the practice, and institutions that failed to document a high compliance to these four measures (>90%) risked losing 1–2% of governmental reimbursement.
While SCIP was a noble start in an effort to improved surgical outcomes, the data after four years of implementation documented little to no reduction in the rate of surgical site infections.
Moving forward, it was realised that a myriad of intrinsic and extrinsic risk factors have a major impact on the evolution of a surgical site infection and that any effort to reduce risk will require a robust effort, embracing multiple, evidence-based interventions targeting those selective risk factors.
Since 2013, numerous peer publications have documented the benefit of embracing a surgical care bundle across the surgical spectrum. To date, there are 13 documented evidence-based practices that have been vetted (High to 1A clinical evidence) in the surgical peer literature for inclusion into a surgical care bundle; those individual elements and quality of evidence include:
The 13 evidence-based interventions have a focal impact on either reducing the element of contamination within the surgical wound prior to closure or enhancing the immune processes within the surgical wound bed.
Of course, this does not preclude the emergence of additional evidence-based practice, since, after all, evidence-based medicine is a moving target, but the present 13 represent in 2018 the current wealth of well-designed clinical studies, meta-analysis and national and international guideline recommendations.
In the past, one of the more controversial interventional elements was the use of antimicrobial (triclosan-coated) sutures. This technology was commercially released in 2002 without the benefit of clinical trial data, making it difficult for surgical practitioners to assess its clinical benefit as a risk reduction intervention.
However, in 2018, there are now multiple mechanistic investigations, clinical trials, meta-analysis and cost-effective studies, documenting the benefit of this technology across the surgical spectrum.10-14 The validation of this technology’s risk-reduction potential lies in the fact that it is now recommended as an evidence-based intervention in multiple SSI prevention guidelines.6-9
The way forward
Going forward, the evidence-based surgical care bundle represents the greatest opportunity for improving surgical outcome across all surgical disciples. Unfortunately, embracing the concept of a care bundle without a mechanism in place to measure compliance negates the benefit of even the most robust interventions.
In light of recent published studies documenting the rate of surgical site infection among selective Australian patient populations, one can muse on the intrinsic benefit of developing standardised evidence-based surgical care bundles as an effort to thwart the significant personal and fiscal morbidity associated with these serious infections.
While we live in an evidence-based clinical world, we cannot overlook the salient commentary of David Sackett, who is viewed along with Archie Cochrane as one of the ‘fathers of evidence-based medicine’. In 1996, he published a paper in the British Medical Journal entitled, ‘Evidence-based medicine; what it is and what it isn’t’, stating: “The practice of evidence-based medicine means integrating individual clinical expertise with the best external evidence from systematic reviews.”
We can never forget the benefit of ‘clinical expertise’ as we move forward in our implementation of an effective evidence-based surgical care bundle.
*Dr Charles E Edmiston, Jr., PhD, CIC, FIDSA, FSHEA, FAPIC is Emeritus Professor of Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin USA.
Read more: http://hospitalhealth.com.au/content/clinical-services/article/reducing-the-risk-of-surgical-site-infections-1031205068#ixzz5RLOa76uO